Barclays PLC Vertex Pharmaceuticals Inc Transaction History

Barclays PLC

$288 Billion
Q1 2024

A detailed history of Barclays PLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Barclays PLC holds 49,800 shares of VRTX stock, worth $22.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

49,800

Previous 1,200 4050.0%

Holding current value

$22.7 Million

Previous $488,000 4165.78%

% of portfolio

0.01%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $4.34 Million - $4.75 Million	10,656 Added 1.32%	817,415 $342 Million
Q4 2023 Feb 15, 2024	BUY	$343.0 - $410.68 $188,650 - $225,874	550 Added 0.07%	806,759 $328 Million
Q3 2023 Nov 07, 2023	BUY	$338.18 - $362.46 $57.6 Million - $61.7 Million	170,224 Added 26.77%	806,209 $280 Million
Q2 2023 Aug 03, 2023	BUY	$314.42 - $351.91 $62.9 Million - $70.4 Million	199,923 Added 45.85%	635,985 $224 Million
Q1 2023 May 04, 2023	SELL	$283.23 - $323.1 $49.8 Million - $56.8 Million	-175,725 Reduced 28.72%	436,062 $137 Million

Q4 2022 Feb 13, 2023	BUY	$285.76 - $321.48 $56.8 Million - $63.9 Million	198,887 Added 48.17%	611,787 $177 Million
Q3 2022 Nov 03, 2022	BUY	$273.83 - $305.53 $8.71 Million - $9.72 Million	31,812 Added 8.35%	412,900 $120 Million
Q2 2022 Aug 12, 2022	SELL	$234.96 - $292.55 $44.9 Million - $55.9 Million	-190,947 Reduced 33.38%	381,088 $107 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $1.9 Million - $2.23 Million	-8,563 Reduced 1.47%	572,035 $149 Million
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $2.11 Million - $2.66 Million	11,895 Added 2.09%	580,598 $128 Million
Q3 2021 Nov 09, 2021	BUY	$181.39 - $202.99 $26.8 Million - $29.9 Million	147,497 Added 35.02%	568,703 $103 Million
Q2 2021 Aug 13, 2021	BUY	$187.49 - $221.1 $8.42 Million - $9.93 Million	44,907 Added 11.93%	421,206 $84.9 Million
Q1 2021 May 13, 2021	SELL	$207.02 - $241.31 $14.4 Million - $16.8 Million	-69,698 Reduced 15.63%	376,299 $80.9 Million
Q4 2020 Feb 11, 2021	BUY	$207.01 - $276.09 $12.4 Million - $16.5 Million	59,702 Added 15.46%	445,997 $105 Million
Q3 2020 Nov 12, 2020	BUY	$255.65 - $303.1 $13.6 Million - $16.1 Million	53,203 Added 15.97%	386,295 $105 Million
Q2 2020 Aug 12, 2020	SELL	$225.48 - $295.8 $78.7 Million - $103 Million	-349,050 Reduced 51.17%	333,092 $96.7 Million
Q1 2020 May 13, 2020	SELL	$199.77 - $247.81 $16.7 Million - $20.8 Million	-83,769 Reduced 10.94%	682,142 $162 Million
Q4 2019 Feb 10, 2020	BUY	$166.71 - $223.91 $57.1 Million - $76.7 Million	342,430 Added 80.86%	765,911 $168 Million
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $10.9 Million - $12.2 Million	65,385 Added 18.26%	423,481 $71.7 Million
Q2 2019 Aug 14, 2019	BUY	$164.61 - $190.37 $14.8 Million - $17.2 Million	90,157 Added 33.65%	358,096 $65.7 Million
Q1 2019 May 15, 2019	SELL	$163.73 - $194.7 $12.6 Million - $15 Million	-77,090 Reduced 22.34%	267,939 $49.3 Million
Q4 2018 Feb 14, 2019	SELL	$151.91 - $192.21 $16.7 Million - $21.2 Million	-110,037 Reduced 24.18%	345,029 $57.2 Million
Q3 2018 Nov 14, 2018	BUY	$167.73 - $192.74 $25.5 Million - $29.3 Million	151,996 Added 50.15%	455,066 $87.7 Million
Q2 2018 Aug 14, 2018	SELL	$145.72 - $169.96 $23.7 Million - $27.6 Million	-162,581 Reduced 34.91%	303,070 $51.5 Million
Q1 2018 May 15, 2018	BUY	$151.6 - $177.13 $9.67 Million - $11.3 Million	63,770 Added 15.87%	465,651 $75.9 Million
Q4 2017 Feb 14, 2018	BUY	$137.28 - $155.55 $18.4 Million - $20.9 Million	134,325 Added 50.2%	401,881 $60.2 Million
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $39.6 Million - $43.4 Million	267,556	267,556 $40.7 Million

Others Institutions Holding VRTX

# of Institutions

1,623

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $117B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account